The nicotinic cholinergic antagonist, dihydro-P-erythroidine, binds to two sites in rat cortical membranes with dissociation constants of 4 and 22 nM and respective apparent B,,, values of 52 and 164 fmol/mg of protein.
protein. Binding to the higher affinity site, defined by the use of 2 nM (3H]dihydro-/3-erythroidine, was saturable, reversible, and susceptible to protein denaturation.
Binding was highest in the thalamus and lowest in the spinal cord and showed preferential enrichment in a synaptosomal subfraction of rat brain. Nicotine displaced [3H]dihydro-/3-erythroidine in a stereospecitic manner, the (-)-isomer being approximately 6 times more potent than the (+)-isomer.
The alkaloid nicotinic agonists, cytisine and lobeline, were potent inhibitors of binding, while acetylcholine in the presence of the cholinesterase inhibitor di-isopropylfluorophosphate was equipotent with (+)-nicotine. Binding was also inhibited by the muscarinic ligands, arecoline, atropine, and oxotremorine.
The nicotinic antagonists mecamylamine, hexamethonium, and pempidine were essentially inactive in displacing [3H]dihydro-fi-erythroidine.
These findings indicate that dihydro-B-erythroidine binds to a nicotinic recognition site in rat brain which is neuromuscular, rather than ganglionic, in nature and that such binding is similar in several respects to that seen with nicotinic agonists. Whether such binding is to a nicotinic, as opposed to nicotinic cholinergic, recognition site or to a "common" nicotinic/muscarinic site is an issue that requires further study.
Acetylcholine
(ACh) receptors in nervous tissue can be divided into muscarinic and nicotinic subclasses on the basis of the effects of the cholinergic agonists, muscarine and nicotine (Triggle, 1971) . In the mammalian CNS, muscarinic cholinergic receptors (mAChRs) can be labeled with agonists such as cismethyldioxolane (Vickroy et al., 1983 ) and antagonists such as quinuclidinyl benzilate (Yamamura and Snyder, 1974) and pirenzepine (Yamamura et al., 1983) . Nicotinic cholinergic receptors (nAChRs) have been labeled with elapid neurotoxins such as a-bungarotoxin (McQuarrie et al., 1976; Oswald and Freeman, 1981) and Nuja nuja siamensis a-toxin (Speth et al., 1977) and the agonists, nicotine and ACh (Yoshida and Imura, 1979; Roman0 and Goldstein, 1980; Martin and Aceto, 1981; Marks and Collins, 1982; Schwartz et al., 1982; Costa and Murphy, 1983; Sloane et al., 1984) .
There is considerable evidence to support the existence of putative nAChR in mammalian brain (Krnjevic, 1976) , and in vivo, nicotine can alter spontaneous activity and brain excitability as well as being antinociceptive (Larson and Silvette, 1975; Costa and Murphy, 1983; Martin et al., 1983 McQuarrie et al., 1976; Schmidt, 1977; Morley et al., 1979) . ACh itself is a weak inhibitor of bungarotoxin binding (Schmidt, 1977) and may be a noncompetitive antagonist of this ligand (Lukas and Bennett, 1979) , perhaps reflecting toxin binding to the putative a-subunit of the mammalian nAChR (Mishina et al., 1984) .
The relative ineffectiveness of the nAChR antagonists, mecamylamine and hexamethonium, in displacing [3H]nicotine binding from rat brain membranes has led to the suggestion that either such binding is noncholinergic or that agonists may induce an agonist-selective nAChR-binding site which is insensitive to antagonists (Abood et al., 1980) . It has been further suggested (Schwartz et al., 1982) that nicotinic agonists and antagonists label different membrane recognition sites. It is also apparent that cr-bungarotoxin and nicotine label different sites in mouse brain membranes (Marks and Collins, 1982) . To examine further the nature of putative nAChRs in mammalian brain tissue, the binding of dihydro+erythroidine (DBE; Fig.  l) , a neuromuscular nicotinic antagonist (Curtis and Ryall, 1966; Nicoll, 1975; Ben Ari et al., 1976) , to rat brain tissue was evaluated.
Materials
and Methods Rat brain tissue was routinely homogenized in 40 vol of ice-cold buffer (50 mM Tris-HCl, pH 7.4) using a Polytron (setting 5.5, 10 set), the resultant homogenate being washed twice by centrifugation (48,000 X g; 4°C) with intermediate resuspension by the Polytron. The final favorably with that obtained for a high affinity DBE-binding site using saturation analysis (Fig. 3) . Over the ligand concentration range 0.1 to 30 nM, specific and total ["HIDBE binding gave evidence of being saturable, whereas nonspecific binding was linear, showing no evidence of saturation. Scatchard (1949) analysis of the specific binding isotherm, using curve fitting analysis as described under "Materials and Methods," gave a biphasic plot (Fig. 3) (Table I) , whereas the P,B fraction had more than twice the total amount of binding as the myelin (P,A) subfraction and 4 times that observed in the mitochondrial (P2C) fraction. Although the increases in the specific activity (femtomoles per milligram of protein) of specific [3H]DBE binding in the P, and PxB fractions are not especially striking, they were significantly different from that observed in the homogenate (Table  I) . Regional analysis of 2 nM [3H]DBE binding showed a significant enrichment in thalamus which had 2.5 times the number of sites on a femtomole per milligram of protein basis that the hypothalamus had (Table II) . Of the other brain regions studied, binding was lowest in the spinal cord, with binding in the remaining brain regions being caudate > hippocampus 2 frontal cortex 2 brainstem > cortex 2 cerebellum. Negligible specific binding was observed in liver membranes (Table II) .
Cholinergic agonists were considerably more potent than antagonists in displacing [3H]DBE (Table III) . The alkaloid, cytisine, a ganglionic agonist, was the most potent compound examined, having an I&,, value 10 times less than that of (-)-nicotine. Lobeline, another agonist alkaloid, was also potent in displacing specific [3H]DBE binding, being 3 times more active Table III ). In the presence of DFP (100 PM), ACh had an I& of 465 nM, being approximately equipotent with (+)-nicotine in displacing ["HI DBE. In the absence of DFP, ACh was some 3 times less potent than in the presence of the cholinesterase inhibitor (Table III) . The nH value of 2.09 compared with a value of 0.96 in the DFPtreated tissue is, therefore, probably a reflection of ACh metabolism. Arecoline, a cholinergic agonist with muscarinic and nicotinic activity (Krnjevic, 1976) , had an I& value of 1.7 pM and was thus some 25 times less active than (-)-nicotine.
Of interest was the fact that arecoline had an nH value that differed significantly from unity (Table III) . MK 212, a putative serotonomimetic, was also equipotent with arecoline in displacing DBE, whereas the piperidinyl analogue of nicotine, anabasine, had an I&, value of 1.97 pM. The neuroleptics, haloperidol and chlorpromazine, were weak inhibitors of binding, as was the putative antidepressant, zimeldine. The muscarinic antagonist, atropine, which was approximately equipotent with the neuroleptics and zimeldine, had a Hill slope value which was significantly less than 1.0 (Table III) , as did the tricyclic antidepressant, desmethylimipramine (DMI ; Table III) , which was some 450 times less potent than (-)-nicotine in displacing DBE binding. The dopamine agonist, apomorphine, and the muscarinic agonist, oxotremorine, were approximately equipotent with DMI yet had nH values close to unity. The psychotomimetic, phencyclidine, which has been reported to interact with nAChR (Aguayo et al., 1981; Oswald et al., 1983) , was a relatively weak inhibitor of DBE binding, as was morphine (Table  III) . The nicotine-cholinergic antagonists, mecamylamine, hexamethonium, and pempidine, and the muscarinic antagonists, scopolamine and pirenzepine, were essentially inactive (I(& values >lOO,OOO nM; Table III) , as were the putative neurotransmitters/neuromodulators, norepinephrine, serotonin, glutamate, GABA, 2-chloroadenosine, lysergic acid diethylamide (LSD), and diazepam.
Discussion
The neuromuscular nAChR antagonist, DBE, was found to bind in a saturable, reversible manner to two high affinity binding sites in rat brain membranes. Examination of the higher affinity site using 2 nM [3H]DBE showed that it was probably protein in nature, since denaturation of the tissue by boiling destroyed binding. In addition, the evidence accumulated indicated that this site showed some preferential localization in synaptosomal subfractions of rat brain (Table I) , although it may be noted that the observed enrichment in binding reflects more properly the total number of sites rather than their density in terms of protein concentration, a finding which may reflect the fact that specific binding was only 50% of the total counts bound. It may also be noted, however, that whereas Schwartz et al. (1982) showed an enrichment of specific [3H]ACh binding in the synaptosomal (P,B) as opposed to myelin (P,A) and mitochondrial (P&) subfractions, such binding was not significantly different from that seen in the initial homogenate.
The regional distribution of the higher affinity [3H]DBE binding site was comparable to that reported for [3H]nicotine (Yoshida and Imura, 1979; Martin and Aceto, 1981; Marks and Collins, 1982) and for [3H]ACh (Schwartz et al., 1982) . Thus, binding ranged from 21 fmol/mg of protein (thalamus) to 1.6 fmol/mg of protein (spinal cord). The actual amount of binding was similar to that observed by both Schwartz et al. (1982) and Marks and Collins (1982) but was somewhat lower than that observed by Yoshida and Imura (1979) and Martin and Aceto (1981) , a finding that may reflect differences in the concentration of radioligands used. However, in both the present study and those of Yoshida and Imura (1979) , Martin and Aceto (1981), and Schwartz et al. (1982) , the thalamus and/or hypothalamus exhibited the highest regional density of putative nAChR-binding sites, a finding which is consistent with electrophysiological evidence for the existence of nicotinic cholinergic receptors in the thalamus (Krnjevic, 1976) . In the study of Marks and Collins (1982), using [3H] nicotine, regional binding was somewhat different in the present study and the others cited, inasmuch as binding was highest in the striatum. Whether the apparent differences in regional binding site density reflect true, as opposed to methodological, differences is an issue that requires resolution.
Binding of 2 nM [3H]DBE to rat brain membranes exhibited stereospecificity, the (-)-isomer of nicotine being approximately 6 times more potent than (+)-nicotine (Table III) . Stereoselectivity has also been observed for the isomers of nicotine using [3H]nicotine (Roman0 and Goldstein, 1980; Costa and Murphy, 1983) and [3H]ACh (Schwartz et al., 1982) , although in these studies the (-)-isomer was 63, 63, and 22 times more potent, respectively, than (+)-nicotine.
The nicotine ganglionic blockers mecamylamine, hexamethonium, and pempidine had little activity at the [3H]DBE-binding site (Table III) , a finding in agreement with the lack of effect of these compounds on nicotine radioligand binding in general (Roman0 and Goldstein, 1980; Marks and Collins, 1982; Schwartz et al., 1982; Costa and Murphy, 1983; Sloan et al., 1984) . These results contrast with the potency of arecoline, atropine, and oxotremorine (Table III) , which are active at the mAChR. It may be noted, however, that the mAChR antagonists scopolamine and pirenzepine were inactive (Table III) . Although the inactivity of the putative neurotransmitter/neuromodulators norepinephrine, serotonin, gluatamate, GABA, diazepam, and 2-chloroadenosine would suggest that the DBE- Vol. 4, No. 12, Dec. 1984 binding site is selectively cholinergic, the present data do not resolve the issue as to why classical nicotinic antagonists do not displace nicotine agonist (Abood et al., 1980; Marks and Collins, 1982; Schwartz et al., 1982; Costa and Murphy, 1983; Sloane et al., 1984) and, in the present instance, antagonist binding.
The unusual pharmacology of the DBE-binding site, the unexpected sensitivity of the binding to a number of psychotropic agents, and the equivocal subcellular distribution raise the issue as to whether the DBE-binding site is an "acceptor" rather than a receptor. Furthermore, it is somewhat unusual for an antagonist recognition site to be more sensitive to agonists (nicotine, anabasine, lobeline) than to antagonists (mecamylamine, hexamethonium, pempidine), while the activity of mAChR ligands (arecoline, atropine, oxotremorine) is also somewhat unexpected.
It may be noted, however, that DBE is a neuromuscular, rather than a ganglionic-type, nicotinic antagonist (Krnjevic, 1976) , and it is possible that the binding site in mammalian brain tissue is more related to the former than to the latter nicotinic receptor. This may in turn explain the lack of effectiveness of the ganglionic blockers on DBE binding. Attempts to study ["Hlmecamylamine binding in mammalian brain tissue have been unsuccessful (M. Williams and J. A. Totaro, unpublished results; S. J. Enna, personal communication), a finding which reinforces the possibility of differences between the putative nAChRs present in brain and those in ganglia. It is also possible, as has been noted from electrophysiological studies (Krnjevic, 1976) , that neurons may have both mAChR and nAChR present on their cell surface, a finding that may reflect on the effectiveness of mAChR ligands at the DBE-binding site.
The binding of [3H]DBE to rat brain membranes is similar in many respects to that seen with ["HInicotine (Marks and Collins, 1982; Costa and Murphy, 1983) and ["H]ACh (Schwartz et al., 1982) , suggesting that the recognition sites binding nicotinic agonists and nicotinic antagonists of the neuromuscular type are similar. Furthermore, the conclusion that nicotinic receptors in brain exist in distinct agonist and antagonist states (Abood et al., 1980; Schwartz et al., 1982 ) based on the ineffectiveness of ganglionic blockers in displacing agonist binding may be premature at the present time. The original observations of Abood et al. (1980) that nAChR may be noncholinergic may be relevant in this context if the nicotinic recognition site(s) in mammalian brain tissue are termed nicotinic rather than nicotinic cholinergic.
From a physiological standpoint, nicotine has pronounced effects in the CNS (Martin et al., 1983) , and it has been reported (Costa and Murphy, 1983) Whether the recognition site to which DBE binds is truly nicotinic in nature and is an "acceptor" or "receptor" is an issue that requires further study. Nonetheless, DBE is the first nicotinic antagonist which has been shown to bind to mammalian brain tissue. Further studies on its binding in both mammalian peripheral and invertebrate tissues such as Torpedo may shed light on the potential physiological significance of putative nicotinic recognition sites in mammalian brain tissue and their relevance to the pathophysiology of nicotine addiction.
